Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Current Assets: 2021-2025

Historic Current Assets for InMed Pharmaceuticals (INM) over the last 4 years, with Sep 2025 value amounting to $10.8 million.

  • InMed Pharmaceuticals' Current Assets rose 48.35% to $10.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.8 million, marking a year-over-year increase of 48.35%. This contributed to the annual value of $12.9 million for FY2025, which is 48.08% up from last year.
  • Latest data reveals that InMed Pharmaceuticals reported Current Assets of $10.8 million as of Q3 2025, which was down 16.07% from $12.9 million recorded in Q2 2025.
  • In the past 5 years, InMed Pharmaceuticals' Current Assets ranged from a high of $16.0 million in Q3 2021 and a low of $5.5 million during Q4 2024.
  • Moreover, its 3-year median value for Current Assets was $10.1 million (2024), whereas its average is $9.5 million.
  • Per our database at Business Quant, InMed Pharmaceuticals' Current Assets crashed by 53.68% in 2024 and then spiked by 48.35% in 2025.
  • Over the past 5 years, InMed Pharmaceuticals' Current Assets (Quarterly) stood at $12.5 million in 2021, then increased by 12.10% to $14.0 million in 2022, then decreased by 15.75% to $11.8 million in 2023, then tumbled by 53.68% to $5.5 million in 2024, then surged by 48.35% to $10.8 million in 2025.
  • Its Current Assets stands at $10.8 million for Q3 2025, versus $12.9 million for Q2 2025 and $6.4 million for Q1 2025.